Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.3600
-0.0014 (-0.39%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Cytosorbents Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.81 | 6.25 | 3.28 | 14.13 | 22.14 | 52.14 |
Cash & Short-Term Investments | 4.81 | 6.25 | 3.28 | 14.13 | 22.14 | 52.14 |
Cash Growth | -58.46% | 90.52% | -76.79% | -36.19% | -57.53% | -27.00% |
Accounts Receivable | 7.15 | 7.55 | 7.32 | 6.06 | 5.66 | 4.52 |
Inventory | 4.48 | 5.28 | 2.73 | 3.38 | 3.46 | 4.77 |
Other Current Assets | 1.31 | 1.55 | 8.27 | 1.83 | 2.49 | 2.87 |
Total Current Assets | 17.76 | 20.63 | 21.6 | 25.4 | 33.76 | 64.3 |
Net Property, Plant & Equipment | 18.28 | 18.75 | 20.51 | 22.12 | 23.35 | 18.57 |
Other Intangible Assets | 2.95 | 3.23 | 3.72 | - | - | - |
Other Long-Term Assets | 1.57 | 1.58 | 1.53 | 5.44 | 6.12 | 6.65 |
Total Assets | 40.56 | 44.18 | 47.37 | 52.96 | 63.23 | 89.52 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.13 | 2.87 | 3.34 | 3.8 | 1.66 | 2.81 |
Accrued Expenses | 5.96 | 6.3 | 6.03 | 7.36 | 7.95 | 10.31 |
Current Portion of Long-Term Debt | 6.65 | - | - | 2.5 | - | - |
Current Portion of Leases | 0.57 | 0.54 | 0.45 | 0.37 | 0.11 | 0.57 |
Total Current Liabilities | 16.3 | 9.71 | 9.83 | 14.04 | 9.71 | 13.69 |
Long-Term Debt | 10.31 | 16.67 | 14 | 2.54 | 5 | - |
Long-Term Leases | 11.75 | 11.9 | 12.44 | 12.9 | 13.14 | 13.25 |
Total Long-Term Liabilities | 22.07 | 28.57 | 26.44 | 15.44 | 18.14 | 13.25 |
Total Liabilities | 38.37 | 38.28 | 36.27 | 29.48 | 27.86 | 26.94 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.06 | 0.06 | 0.06 | 0.05 | 0.04 | 0.04 |
Additional Paid-in Capital | 321.57 | 321.02 | 310.81 | 306.19 | 287 | 283.19 |
Accumulated Other Comprehensive Income | -2.1 | -2.98 | 4.25 | 0.53 | 2.33 | 0.53 |
Retained Earnings | -317.34 | -312.21 | -304.01 | -283.29 | -254 | -221.19 |
Shareholders' Equity | 2.19 | 5.9 | 11.11 | 23.48 | 35.37 | 62.58 |
Total Liabilities & Equity | 40.56 | 44.18 | 47.37 | 52.96 | 63.23 | 89.52 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 29.28 | 29.11 | 26.89 | 18.31 | 18.25 | 13.82 |
Net Cash (Debt) | -24.46 | -22.86 | -23.61 | -4.18 | 3.89 | 38.32 |
Net Cash Growth | - | - | - | - | -89.84% | -45.57% |
Net Cash Per Share | -0.38 | -0.37 | -0.43 | -0.09 | 0.09 | 0.88 |
Book Value | 2.19 | 5.9 | 11.11 | 23.48 | 35.37 | 62.58 |
Book Value Per Share | 0.03 | 0.09 | 0.20 | 0.53 | 0.81 | 1.44 |
Tangible Book Value | -0.76 | 2.68 | 7.39 | 23.48 | 35.37 | 62.58 |
Tangible Book Value Per Share | -0.01 | 0.04 | 0.14 | 0.53 | 0.81 | 1.44 |